Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589741 | 0.92 | MTNR1A (0.40) | OPRM1MTNR1AKMT2AMTNR1BNQO2 | |
| SCHEMBL4911889 | 0.75 | OPRM1 (0.42) | POLA1OPRM1CYP3A4CYP2C9TSHR | |
| SCHEMBL11459392 | 0.73 | BRD4 (0.42) | POLA1OPRM1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1470331 | 0.70 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL10998258 | 0.70 | KDM1A (0.46) | OPRM1CYP2C19ALDH1A1KMT2A | |
| SCHEMBL5859227 | 0.69 | CYP19A1 (0.53) | MTNR1AKMT2AMTNR1B | |
| SCHEMBL2305878 | 0.69 | CYP26A1 (0.56) | MTNR1AKMT2AMTNR1B | |
| SCHEMBL14005909 | 0.68 | OPRM1 (0.36) | POLA1OPRM1ALDH1A1OPRK1 | |
| SCHEMBL11458608 | 0.68 | OPRM1 (0.39) | POLA1OPRM1CYP3A4CYP2C9TSHR | |
| SCHEMBL11457213 | 0.68 | OPRM1 (0.39) | OPRM1CYP3A4CYP2C9CYP2C19MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1904482-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | IDO1, INMT, IDO2 | POLA1 3445/4885OPRM1 866/4885CYP3A4 321/4885 |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | POLA1 4705/4885OPRM1 3358/4885CYP3A4 2739/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | POLA1 4197/4885OPRM1 610/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.